Cancer Chemotherapy and Pharmacology

Journal

Publication Venue For

  • Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.  83:551-559. 2019
  • The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.  81:413-417. 2018
  • Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.  80:1209-1217. 2017
  • DNA topoisomerase-targeting chemotherapeutics: what’s new?.  80. 2017
  • Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients.  78:509-515. 2016
  • Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).  76:949-955. 2015
  • Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: Remission and lack of host toxicity.  69:1449-1455. 2012
  • Lack of in vivo cross-resistance with 4′-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.  68:399-403. 2011
  • A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.  67:891-897. 2011
  • Sunitinib in combination with docetaxel in patients with advanced solid tumors: A phase I dose-escalation study.  66:669-680. 2010
  • A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer.  65:227-234. 2010
  • Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: Effect on chemotherapy toxicity and efficacy.  63:731-743. 2009
  • Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity.  62:85-96. 2008
  • Androgen and c-Kit receptors in desmoplastic small round cell tumors resistant to chemotherapy: Novel targets for therapy.  59:429-437. 2007
  • Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor.  58:692-698. 2006
  • 5-(Phenylthio)acyclouridine: A powerful enhancer of oral uridine bioavailability: Relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens.  55:541-551. 2005
  • Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.  55:411-419. 2005
  • Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.  54:71-78. 2004
  • Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer.  52:399-404. 2003
  • Preclinical antitumor activity of 4′-thio-β-D-arabinofuranosylcytosine (4′-thio-ara-C).  51:422-426. 2003
  • Enhancement of the bioavailability of oral uridine by coadministration of 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: Implications for uridine rescue regimens in chemotherapy.  48:389-397. 2001
  • Modulation of the pharmacokinetics of endogenous plasma uridine by 5-(phenylthio)acyclouridine, a uridine phosphorylase inhibitor: Implications for chemotherapy.  48:145-150. 2001
  • Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2', 3', 5'-tri-O-acetyluridine, a prodrug of uridine: Relevance to uridine rescue in chemotherapy.  46:235-240. 2000
  • Modulation of plasma uridine concentration by 5- (phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: Relevance to chemotherapy.  45:351-361. 2000
  • Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma.  46:173-179. 2000
  • Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I.  41:257-267. 1998
  • Etoposide sensitivity of radioresistant human glioma cell lines.  41:93-97. 1997
  • Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion.  40:376-384. 1997
  • The significance of the sequence of administration of topotecan and etoposide.  39:109-112. 1996
  • Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.  38:459-465. 1996
  • Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.  37:14-22. 1995
  • Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer.  33:472-476. 1994
  • Yeast Saccharomyces cerevisiae as a model system to study the cytotoxic activity of the antitumor drug camptothecin.  34. 1994
  • Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.  31:167-169. 1992
  • 2,4-Diamino-6-(bis-2-chloroethyl)aminomethyl pteridine - A new potent anticancer drug.  13:73-74. 1984

    • International Standard Serial Number (issn)

  • 0344-5704

    • Electronic International Standard Serial Number (eissn)

  • 1432-0843